Parimer Scientific

Parimer Scientific

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Parimer Scientific is a lean, privately-owned CDMO based in San Diego, California, that provides end-to-end development and manufacturing services for novel chemical entities, APIs, and liquid medical devices. It differentiates itself through a client-centric model that includes potential equity-for-services arrangements, waiving IP rights developed under contract, and a focus on navigating complex FDA and ICH regulatory pathways. With a core team of PhD scientists, the company supports clients from preclinical R&D through clinical trials and commercial manufacturing, targeting the need for agile, U.S.-based manufacturing partners in the biotech and pharmaceutical sectors.

DiagnosticsMedical Devices

Technology Platform

Integrated CDMO services for chemical process development, cGMP API manufacturing, and regulatory support for drug substances and liquid medical devices.

Opportunities

Growing demand for U.S.-based, flexible CDMO services from virtual and small biotech companies provides a strong tailwind.
The ability to take equity in clients offers potential for significant financial upside beyond service fees.
Specialization in complex areas like liquid medical devices and DEA-controlled substances creates defensible niche expertise.

Risk Factors

Revenue is highly dependent on the funding health of the startup biotech sector, which is cyclical.
Operational risk is high due to stringent cGMP requirements; a single quality failure could be catastrophic.
The small team and private structure, while agile, may limit scalability and create key-person dependencies.

Competitive Landscape

Parimer competes against large, global CDMOs (e.g., Lonza, Catalent) and other small-to-mid-sized U.S. CDMOs. It differentiates through its lean, scientist-led model, flexibility in deal structures (equity), and explicit waiver of client IP rights. Its focus on early-stage companies and U.S. manufacturing is a key competitive positioning against lower-cost offshore providers.